Business Context and Reporting Period
Company: Conduit Pharmaceuticals Inc. (CDT)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2024
Business Model: Clinical-stage biopharmaceutical company acting as a conduit to license, develop, and monetize clinical assets from major pharmaceutical companies. The company focuses on repurposing assets using solid-form technology and AI-driven decision-making.
Key Assets:
- AZD1656: Glucokinase activator for autoimmune disorders (Lupus, ANCA Vasculitis).
- AZD5904: Myeloperoxidase inhibitor for idiopathic male infertility.
- AZD5658: Glucokinase activator for autoimmune disorders.
- Completed a 1-for-100 reverse stock split effective January 24, 2025.
- Entered into a License Agreement with AstraZeneca (August 2024) for the above assets.
- Entered into a Services Agreement with Sarborg Limited (related party) for AI/cybernetic technology services.
Key Financial Metrics
| Metric (in thousands) | 2024 | 2023 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(17,802) | $(535) |
| Operating Loss | $(15,419) | $(5,262) |
| Research & Development Expenses | $3,378 | $90 |
| General & Administrative Expenses | $12,041 | $5,173 |
| Cash and Cash Equivalents (Year End) | $554 | $4,228 |
| Accumulated Deficit | $(29,101) | $(11,299) |
| Total Liabilities | $10,986 | $7,681 |
| Stockholders' Deficit | $(6,793) | $(457) |
Note: The filing text does not provide specific gross margin or operating margin percentages due to zero revenue.
Material Changes vs. Prior Period
- Net Loss: Increased significantly from $0.5 million in 2023 to $17.8 million in 2024. This was driven by increased operating expenses and non-cash losses on warrant issuances and debt extinguishments.
- R&D Expenses: Surged 3,653% to $3.4 million, primarily due to a $3.1 million upfront payment (cash and stock) to AstraZeneca for the new license agreement.
- G&A Expenses: Increased 133% to $12.0 million, driven by higher salaries, stock-based compensation, D&O insurance, and professional fees associated with public company compliance.
- Liquidity: Cash and cash equivalents decreased by approximately $3.7 million to $0.6 million. The company reported a working capital deficiency.
- Debt Structure: Significant restructuring of debt occurred, including the issuance of convertible notes to A.G.P. and Nirland (related party), and the conversion of deferred commissions into convertible notes.
Guidance, Outlook, Risks, and Contingencies
Going Concern
The independent auditor has issued an explanatory paragraph indicating substantial doubt regarding the Company's ability to continue as a going concern for at least 12 months from the filing date. The company requires substantial additional funding to meet obligations and sustain operations.
Outlook and Strategy
- Development Plan: Intends to conduct Phase II clinical trials for AZD1656 (Lupus/ANCA Vasculitis) and AZD5904 (Male Infertility).
- Monetization: Plans to license assets to third parties following successful Phase II trials rather than commercializing internally.
- Capital Needs: Estimates working capital requirements of approximately $22.9 million for the next 12 months. Plans to fund operations through the At-The-Market (ATM) Sales Agreement, debt financing, and equity raises.
Material Risks
- Regulatory Approval: No products are approved; success depends on clinical trial outcomes and FDA/regulatory approval.
- Intellectual Property: Facing patent entitlement proceedings from St George Street Capital regarding the AZD1656 co-crystal patent.
- Legal Proceedings: Litigation with Strand Hanson Limited regarding advisory fees (accrued liability of $0.4 million).
- Nasdaq Compliance: Received deficiency letters regarding Bid Price, MVPHS, and MVLS rules. Granted an extension to regain compliance by transferring to the Nasdaq Capital Market.
- Internal Controls: Material weaknesses identified in internal control over financial reporting, including limited segregation of duties and lack of formal review processes.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $12.0 million remaining under the ATM Sales Agreement and the ability to raise additional capital given the "substantial doubt" going concern warning.
- Debt Obligations: Review the terms of the convertible notes with A.G.P. and Nirland, specifically conversion prices and potential dilution, noting that some notes were in default as of year-end but settled subsequently.
- IP Litigation: Monitor the status of the patent dispute with St George Street Capital regarding the AZD1656 co-crystal, which is central to the company's value proposition.
- Nasdaq Status: Confirm the successful transfer to the Nasdaq Capital Market and ongoing compliance with listing standards to avoid delisting.
- Related Party Transactions: Scrutinize the terms of the Sarborg Services Agreement and Nirland debt instruments, given the involvement of board members.
- Internal Controls: Assess the progress of remediation plans for the identified material weaknesses in financial reporting.